Call for Papers - Clinical translation of targeted proteomics

Tiannan Guo: Westlake University, China
Tiannan Guo is an associate professor at Westlake University. He also leads the iMarker lab at Westlake Laboratory. His research focuses on proteomic technological development and AI-empowered applications in disease diagnosis and therapeutics. He and colleagues developed pressure-cycling technology coupled with SWATH/DIA mass spectrometry to enable effective proteomic analysis of biopsy tissues. His team reported the first proteomic and metabolic profiles of COVID-19 sera, the first proteomic landscape for COVID-19 autopsies, and the first proteomic classifier for diagnosing thyroid nodules. More in www.guomics.com.



Ed Nice: Monash University, Australia
Ed Nice is a Professor at Monash University where he is Head of Clinical Biomarker Discovery and Validation and scientific advisor to the Monash Antibody Technologies Facility, for which he was director from 2009 to 2013. He is also a Visiting Professor at Sichuan University/West China Hospital. His long-term research interests have been in protein and peptide micropurification, biomarker discovery and validation, SPR analysis, high throughput monoclonal antibody production and validation, and clinical biomarker assay development, with a strong translational focus on colorectal cancer, especially the field of faecal proteomics for colorectal cancer detection and surveillance. He is actively involved in the Human Proteome Organization (HUPO).



Stephen Pennington: UCD Conway Institute, Ireland
Stephen Pennington graduated from Imperial College of Science and Technology (Imperial College London) with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge.  His research team in University College Dublin is currently focused on the translation of novel protein biomarkers to clinical diagnostic tests. He founded the UCD spin out company, Atturos in late 2016 and was awarded UCD's Innovator of the Year in 2018. Steve is currently Professor of Proteomics and Senior Fellow, UCD Conway Institute, President of the British Society of Proteome Research, and past President of HUPO. Most recently, he and a rheumatologist colleague are leading an IMI funded European consortium (HIPPOCRATES; https://hippocrates-imi.eu/) which seeks to address key unmet needs in Psoriatic Disease.

Henry Rodriguez: National Institutes of Health, USA
Henry Rodriguez is the Founding Director of the Office of Cancer Clinical Proteomics Research at the National Cancer Institute, National Institutes of Health. Recently, he served as Assistant Director for Strategic Health and Cancer Science, in the Executive Office of the President at the White House. A cell and molecular biologist with a background in business, Dr. Rodriguez’s biomedical research has focused on mechanisms of cancer in basic and clinical science, and the development of measurement science, standards, and technology. Dr. Rodriguez has authored more than 150 original research papers, including co-editing a best-selling book on oxidative stress and aging.